Precision in the Service of Animal Health

The expansion of Ceva-Phylaxia’s facility in Monor aims to increase the company’s veterinary vaccine manufacturing capacity. In the first phase of the project, approximately 8,000 sqm of new production space is being developed, comprising a new manufacturing building and a dedicated utility building. The new facility will enable the production of multi-component inactivated veterinary vaccines as well as fermentation-based antigen manufacturing.

The first phase of the project commenced at the end of 2024, and Realiscon joined the ongoing construction in May 2026, providing architectural, mechanical and electrical technical supervision, together with fire safety consultancy services.

Engineering Precision in a Highly Specialised Environment

Facilities designed for veterinary vaccine manufacturing require considerably higher technical standards than conventional industrial developments. The new building incorporates pharmaceutical cleanroom technology, where every stage of construction must comply with stringent quality and regulatory requirements. The coordination of multiple engineering disciplines, the integration of mechanical and electrical building systems, and the installation of specialised technologies are all essential to the successful delivery of the project.

Structural works were completed by summer 2026, followed by the interior fit-out and specialist technology installations.

Wastewater Treatment Supporting Production

The second phase of the development commenced in September 2026. It includes the construction of a wastewater treatment plant with a treatment capacity of 350 m³, designed for the on-site treatment and purification of wastewater generated during vaccine manufacturing. The wastewater treatment plant forms part of the infrastructure required for the safe operation of the new production facility, and its delivery is therefore closely linked to the first phase.

Realiscon’s technical supervision scope also extends to the construction of the second phase. Both phases are scheduled for completion in Q2 2027.